Table 7.
Scenario analysis results: total costs for all comorbidities for the projected 5-year time horizon among mild-to-moderate AD patients and matched non-AD controls
| Comorbidities | 2018a | 2019a | 2020a | 2021a | 2022a | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mild-to-moderate AD | Matched non-AD control | Mild-to-moderate AD | Matched non-AD control | Mild-to-moderate AD | Matched non-AD control | Mild-to-moderate AD | Matched non-AD control | Mild-to-moderate AD | Matched non-AD control | |
| Asthma | €114,522,148.08 | €54,898,692.76 | €115,206,951.59 | €55,226,968.28 | €115,832,619.85 | €55,526,896.02 | €116,410,079.37 | €55,803,713.38 | €116,950,361.25 | €56,062,709.77 |
| Depression | €82,500,340.35 | €43,929,732.92 | €82,993,664.34 | €44,192,417.79 | €83,444,388.03 | €44,432,418.88 | €83,860,382.01 | €44,653,927.11 | €84,249,595.11 | €44,861,175.07 |
| Anxiety | €43,245,352.55 | €16,361,986.84 | €43,503,945.05 | €16,459,825.95 | €43,740,207.17 | €16,549,216.31 | €43,958,264.53 | €16,631,718.86 | €44,162,283.78 | €16,708,910.05 |
| IHD | €17,885,331.15 | €9,831,377.68 | €17,992,279.34 | €9,890,165.97 | €18,089,992.18 | €9,943,877.69 | €18,180,175.93 | €9,993,450.75 | €18,264,553.83 | €10,039,832.39 |
| Sleep disorder | €14,501,535.95 | €5,993,140.12 | €14,588,250.20 | €6,028,977.06 | €14,667,476.37 | €6,061,719.36 | €14,740,597.91 | €6,091,938.75 | €14,809,012.02 | €6,120,212.68 |
| Smoking | €10,124,429.50 | €12,427,065.23 | €10,184,970.15 | €12,501,374.86 | €10,240,282.89 | €12,569,267.58 | €10,291,333.61 | €12,631,928.95 | €10,339,097.78 | €12,690,556.31 |
| Obesity | €6,321,910.83 | €2,646,381.28 | €6,359,713.70 | €2,662,205.74 | €6,394,252.17 | €2,676,663.70 | €6,426,129.33 | €2,690,007.63 | €6,455,954.30 | €2,702,492.50 |
| Skin infections | €6,253,599.51 | €1,668,407.15 | €6,290,993.91 | €1,678,383.66 | €6,325,159.17 | €1,687,498.66 | €6,356,691.89 | €1,695,911.32 | €6,386,194.59 | €1,703,782.39 |
| AR | €1,331,446.79 | €361,144.06 | €1,339,408.38 | €363,303.58 | €1,346,682.47 | €365,276.62 | €1,353,396.07 | €367,097.63 | €1,359,677.45 | €368,801.40 |
| ACD | €1573.38 | €137.01 | €1582.79 | €137.83 | €1591.38 | €138.58 | €1599.31 | €139.27 | €1606.74 | €139.91 |
AD patients were propensity score matched with up to three non-AD controls based on demographics including age, sex, socio-economic status and practice ID
AD atopic dermatitis, ACD allergic contact dermatitis, AR allergic rhinitis, IHD ischaemic heart disease
aThe study projected 849,296 mild-to-moderate AD patients and matched non-AD controls in 2018, 854,374 mild-to-moderate AD patients and matched non-AD controls in 2019, 859,014 mild-to-moderate AD patients and matched non-AD controls in 2020, 863,297 mild-to-moderate AD patients and matched non-AD controls in 2021, 867,303 mild-to-moderate AD patients and matched non-AD controls in 2022